

2011 PHARMACEUTICALS RESEARCH REVIEW	XX
FOREWORD	XX

CHAPTER ONE: GLOBAL MARKETS FOR MARINE-DERIVED
PHARMACEUTICALS (PHM101A)..... 1

INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THIS STUDY	1
SCOPE OF REPORT.....	2
INTENDED AUDIENCE.....	2
METHODOLOGY.....	2
INFORMATION SOURCES	2
ABOUT THE AUTHOR	3
RELATED BCC REPORTS.....	3
BCC ONLINE SERVICES	4
DISCLAIMER.....	4
EXECUTIVE SUMMARY.....	4
<i>TABLE 1 GLOBAL FORECAST FOR MARINE-DERIVED DRUGS BY TYPE, THROUGH 2016 (\$ MILLIONS).....</i>	<i>5</i>
<i>FIGURE 1 GLOBAL FORECAST FOR MARINE-DERIVED DRUGS, 2010–2016 (\$ MILLIONS).....</i>	<i>6</i>
EXECUTIVE SUMMARY (CONTINUED)	7
INVESTMENT AND PATH FORWARD	8
INVESTMENT AND PATH FORWARD (CONTINUED).....	9
KEY DRIVERS.....	10
KEY CHALLENGES.....	11
KEY TRENDS.....	11
DEVELOPMENT OF MICROBES SYMBIOTIC WITH MARINE INVERTEBRATES	12
USE OF ALGAE IN NOVEL WAYS	12
GREATER USE OF ESTABLISHED MARINE LIFE LIBRARIES.....	13
CONTINUED FOCUS ON CANCER.....	13
EXPANSION OF KNOWLEDGE AND USE OF CONOPEPTIDES	13
IMMUNE CELL INDUCEMENT THERAPY.....	14
INVESTMENT LANDSCAPE.....	14
KEY INVESTMENTS/COLLABORATIONS IN MARINE- DERIVED DRUG DEVELOPMENT.....	15
Abbott Laboratories and Seattle Genetics.....	15
Algenics, IFREMER, Roquette Group	15
Aphios Corp., Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, Baxter Healthcare, Sigma-Aldrich	15

Aquapharm Biodiscovery, Ltd. and Albany Molecular Research Group	16
ArcticZymes, Universities in Tromsø, Trondheim (NTNU/Norway), and Umeå (Sweden)	16
ASKA and Yakult Honsha	16
AstraZeneca (MedImmune) and Xenome	16
Azur Pharma and Eisai	17
Boehringer Ingelheim, Sigma-Tau, Pacira	17
Cognetix, Inc. and the University of Utah	17
Genzyme and Abbott Laboratories	17
Gilead Sciences, Inc. and UC Santa Cruz	17
GlaxoSmithKline and Pfizer	18
GlaxoSmithKline/Pronova, Affiris, and Stellar Biotechnologies	18
GlycoMar and Verona Pharma	18
Johnson & Johnson, PharmaMar, and Taiho Pharmaceuticals	18
National Cancer Institute and Bristol-Myers Squibb	19
Nautilus Biosciences Canada, Inc. and the NRC-INH on the Campus of UPEI	19
Scripps Institution of Oceanography, Trius Therapeutics, and Nereus Pharmaceuticals	19
Seattle Genetics, Astellas, CellDex, Millennium	20
Stellar Biotechnologies, Bayer Innovation, Amgen, Merck, Biovest, Néovacs, Affiris, GlaxoSmithKline	21
Triton Biopharma, University of Mississippi, PharmaMar	21
OVERVIEW	21
HISTORY OF MARINE DRUGS	21
History of Marine Drugs (Continued)	22
History of Marine Drugs (Continued)	23
<i>TABLE 2 KEY DATES IN MARINE-DERIVED DRUG HISTORY</i>	24
History of Marine Drugs (Continued)	25
<i>TABLE 3 GROWTH IN THE INTEREST IN MARINE NATURAL PRODUCTS BASED ON THE NUMBER OF PRODUCTS DESCRIBED IN SCIENTIFIC JOURNALS, 1999–2004</i>	26
MAJOR CATEGORIES OF MARINE DRUGS	26
Main Chemical Classes	26
Phenols	26
Steroids	26
Ether	27
Strigolactones	27
Peptides	27
Main Marine Life Groupings	28
Marine Microorganisms	28

Marine Algae.....	29
Marine Invertebrates.....	30
• Porifera.....	30
• Discodermolide	30
• Cnidarians.....	31
• Ctenophora.....	31
• Bryozoa.....	31
• Mollusca	32
• Echinoderms	32
• Protozoa.....	33
• Chordates.....	33

<i>FIGURE 2 THE TUNICATE ECTEINASCIDIA TURBINATE FROM WHICH YONDELIS (TRABECTEDIN) FOR CANCER TREATMENT IS MADE</i>	<i>34</i>
<i>FIGURE 3 MARINE SPECIES PER PHYLUM BASED ON WORMS</i>	<i>35</i>
<i>FIGURE 4 APPROXIMATION OF KNOWN VERSUS POSSIBLE SPECIES WITHIN THREE PHYLA, 2011.....</i>	<i>36</i>

CHAPTER TWO: EMERGING REGIONAL MARKETS FOR THERAPEUTIC DRUGS (PHM076A).....	37
INTRODUCTION	37
STUDY GOALS AND OBJECTIVES	37
REASONS FOR DOING THE STUDY.....	37
SCOPE OF REPORT.....	38
INTENDED AUDIENCE.....	39
METHODOLOGY AND INFORMATION SOURCES.....	39
ANALYST CREDENTIALS	40
RELATED BCC REPORTS.....	40
SUMMARY	40
<i>TABLE 4 TOTAL EMERGING GEOGRAPHIC MARKETS BY REGION, THROUGH 2015 (\$ MILLIONS).....</i>	<i>41</i>
<i>FIGURE 5 TOTAL EMERGING GEOGRAPHIC MARKETS, BY REGION, 2007–2015 (\$ MILLIONS).....</i>	<i>42</i>
OVERVIEW	43
<i>TABLE 5 ECONOMIC STATISTICS AND GROSS DOMESTIC PRODUCTION FOR EMERGING COUNTRIES, 2008 (\$ BILLIONS/%).....</i>	<i>44</i>
OVERVIEW (CONTINUED)	45
EMERGING MARKET OPPORTUNITIES	46
EMERGING MARKET CHALLENGES	47

CHAPTER THREE: BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS (PHM075A)	48
INTRODUCTION	48
STUDY GOALS AND OBJECTIVES	48

REASONS FOR DOING THIS STUDY	48
SCOPE OF REPORT.....	48
INTENDED AUDIENCE.....	49
METHODOLOGY.....	49
INFORMATION SOURCES	49
ABOUT THE AUTHOR	49
RELATED BCC REPORTS.....	49
EXECUTIVE SUMMARY.....	50
EXECUTIVE SUMMARY (CONTINUED)	51
EXECUTIVE SUMMARY (CONTINUED)	52
EMERGING BBB TECHNOLOGY MARKET.....	53
EMERGING BBB TECHNOLOGY ... (CONTINUED)	54
EMERGING BBB TECHNOLOGY ... (CONTINUED)	55
KEY DRIVERS.....	56
KEY CHALLENGES.....	56
MAJOR TRENDS.....	57
<i>TABLE 6 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2015 (\$ MILLIONS).....</i>	<i>58</i>
<i>FIGURE 6 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2015 (\$ MILLIONS).....</i>	<i>59</i>
OVERVIEW.....	59
TODAY'S PHARMA MARKET.....	59
<i>FIGURE 7 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS BY REGION, 2009 AND 2015 (% OF GLOBAL SALES).....</i>	<i>60</i>
<i>FIGURE 7 (CONTINUED)</i>	<i>61</i>
<i>FIGURE 8 EMERGING MARKETS' GROWTH IN PHARMACEUTICAL SALES, 2015 (ESTIMATED \$ BILLIONS).....</i>	<i>62</i>
<i>FIGURE 9 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS BY REGION, 2015* (\$ MILLIONS).....</i>	<i>63</i>
<i>FIGURE 9 (CONTINUED)</i>	<i>64</i>
BIOLOGICS	64
<i>FIGURE 10 INVESTMENT IN BIOLOGICS AS A PERCENTAGE OF TOTAL R&D, 2009 (% OF TOTAL R&D).....</i>	<i>65</i>
GENERICS SIGNAL NEED FOR INNOVATION	66
NEUROFOCUSING IN THE PHARMA INDUSTRY	67
<i>FIGURE 11 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2009 (\$ BILLIONS).....</i>	<i>68</i>
<i>FIGURE 12 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, 2015 AND 2017 (NUMBER OF UNITS).....</i>	<i>69</i>
<i>FIGURE 13 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS BY INDICATION, 2015 AND 2017 (NUMBER OF UNITS PER INDICATION)</i>	<i>70</i>
NEUROFOCUSING IN THE ... (CONTINUED)	71

<i>TABLE 7 TOP PHARMA COMPANIES BY REVENUE, 2009 (\$</i>	
<i>BILLIONS)</i>	72
EMERGING BBB TECHNOLOGY MARKET.....	73
BRIEF HISTORY OF BBB.....	73
BLOOD BRAIN BARRIER DEFINED.....	74
BBB COMPONENTS.....	75
<i>FIGURE 14 PARTS OF THE BBB</i>	76
BBB ILLUSTRATED.....	76
MAIN AREAS OF THE BRAIN.....	77
<i>FIGURE 15 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO</i>	
<i>BLOOD VESSELS</i>	78
TREATING DISEASE AND THE BBB.....	79
MENINGITIS.....	79
MULTIPLE SCLEROSIS (MS).....	80
ENCEPHALITIS.....	80
ALZHEIMER'S DISEASE (AD).....	81
PARKINSON'S DISEASE (PD).....	82
BBB TECHNOLOGY CLASSIFICATION.....	83
MOST COMMON BBB TECHNOLOGY.....	83
MOST COMMON BBB TECHNOLOGY (CONTINUED).....	84
CHALLENGES WITH THE MOST COMMON TECHNOLOGY	
USED.....	85
TRANSPORT CONSIDERATIONS.....	85
BYPASSING THE BBB.....	85
BBB TECHNOLOGY DETAILED.....	86
CHEMICAL TRANSPORT SYSTEMS.....	86
BIOLOGICAL CARRIER OR TRANSPORT SYSTEMS.....	87
PHYSICAL FORCE (ENERGETIC) OPENING THROUGH	
SOUND WAVES (TARGETED ULTRASOUND).....	87
Physical Force (Energetic) ... (Continued)).....	88
Physical Force (Energetic) ... (Continued)).....	89
<i>FIGURE 16 METHODS OF CROSSING THE BBB</i>	90
ENHANCING BIOLOGICAL TRANSPORT SYSTEM TECHNIQUES.....	90
NANOPARTICLES AND LIPOSOMES.....	91
NANOPARTICLES.....	91
<i>TABLE 8 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB</i>	
<i>TECHNOLOGY</i>	92
Challenges with Nanoparticles.....	93
Liposomes.....	93
Liposomes (Continued).....	94
Liposomes (Continued).....	95
 CHAPTER FOUR: DRUGS FOR TREATING MENTAL DISORDERS:	
TECHNOLOGIES AND GLOBAL MARKETS (PHM074A).....	96

INTRODUCTION	96
STUDY GOALS AND OBJECTIVES	96
REASONS FOR DOING THIS STUDY	96
SCOPE OF REPORT.....	96
METHODOLOGY AND INFORMATION SOURCES	97
INTENDED AUDIENCE.....	97
ANALYST CREDENTIALS	97
RELATED REPORTS	98
SUMMARY.....	98
<i>TABLE 9 GLOBAL MENTAL HEALTH PHARMACEUTICAL</i>	
<i>INDUSTRY BY DRUG CATEGORY, THROUGH 2015 (\$ BILLIONS)</i>	<i>99</i>
<i>FIGURE 17 GLOBAL MENTAL HEALTH PHARMACEUTICAL</i>	
<i>INDUSTRY BY DRUG CATEGORY, 2009–2015 (\$ BILLIONS).....</i>	<i>100</i>
INTRODUCTION	100
HISTORICAL OVERVIEW.....	100
SCIENTIFIC BREAKTHROUGHS IN MENTAL HEALTH	
RESEARCH.....	101
DRIVERS AND CHALLENGES OF THE MENTAL HEALTH	
PHARMACEUTICAL MARKET.....	102
MENTAL HEALTH ORGANIZATIONS.....	103
CITIZENS COMMISSION ON HUMAN RIGHTS (CCHR).....	103
NATIONAL ALLIANCE OF MENTAL ILLNESS (NAMI).....	103
MENTAL HEALTH AMERICA (MHA).....	104
NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH).....	104
GENERAL OVERVIEW OF THE MENTAL HEALTH	
PHARMACEUTICAL MARKET.....	104
<i>TABLE 10 GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET</i>	
<i>SHARES BY DRUG CATEGORY, 2010 (%).....</i>	<i>104</i>
<i>FIGURE 18 GLOBAL MENTAL HEALTH PHARMACEUTICAL</i>	
<i>MARKET SHARES BY DRUG CATEGORY, 2010 (%).....</i>	<i>105</i>
DIAGNOSTICS FOR MENTAL ILLNESSES	106
OVERVIEW	106
Overview (Continued).....	107
Overview (Continued).....	107
<i>TABLE 11 U.S. LIFETIME PREVALENCE OF MENTAL HEALTH</i>	
<i>DISORDERS BY TYPE OF ILLNESS, 2009 (%).....</i>	<i>108</i>
GENETIC FACTORS OF MENTAL HEALTH DISORDERS	
AND BIOMARKER DEVELOPMENT	109
<i>TABLE 12 GENETIC FACTORS ASSOCIATED WITH MENTAL</i>	
<i>HEALTH DISORDERS AND CURRENT DIAGNOSTIC TESTS.....</i>	<i>109</i>
Bipolar Disorder	109
<i>TABLE 13 RISK OF DEVELOPING BIPOLAR DISORDER BASED ON</i>	
<i>FAMILIAL RELATIONSHIP (%).....</i>	<i>110</i>
ANK3/CACNA1C Gene Candidates.....	110

GRK3.....	110
NEW DIAGNOSTIC TOOLS FOR BIPOLAR DISORDER BASED ON GENETIC FINDINGS.....	111
Schizophrenia	111
<i>TABLE 14 U.S. STATISTICAL RISK OF DEVELOPING SCHIZOPHRENIA BASED ON FAMILIAL RELATIONSHIP (%)</i>	<i>111</i>
New Diagnostics for Schizophrenia.....	112
CMYA 5	112
Chromosomal Deletions.....	112
Depression.....	113
New Diagnostics for Depression.....	113
BIOMARKER MARKET FOR CNS DISORDERS.....	114
<i>TABLE 15 GLOBAL MARKET FORECAST FOR BIOMARKERS FOR CNS DISORDERS AND DIAGNOSTICS TESTS, THROUGH 2015 (\$ MILLIONS)</i>	<i>114</i>
Recent Examples of Biomarker Research Development for Mental Disorders.....	115
Examples of Industry-Academia Collaborations as Drivers of Biomarker Development	116
PSYCHOTHERAPY FOR THE TREATMENT OF MENTAL DISORDERS.....	117
<i>TABLE 16 U.S. PSYCHOTHERAPY TREATMENT STATISTICS, 2009</i>	<i>117</i>
CHAPTER FIVE: GENERIC DRUGS: THE GLOBAL MARKET (PHM009F)	118
INTRODUCTION	118
STUDY GOALS AND OBJECTIVES	118
REASONS FOR DOING THE STUDY.....	118
SCOPE OF REPORT.....	119
MARKET ANALYSES AND FORECASTS.....	119
METHODOLOGY.....	120
INTENDED AUDIENCE.....	120
INFORMATION SOURCES	120
ANALYST CREDENTIALS	120
RELATED REPORTS	120
SUMMARY.....	121
MARKET SIZE AND EVOLUTION.....	122
<i>TABLE 17 MAJOR GENERICS MARKETS, THROUGH 2016 (\$ BILLIONS)</i>	<i>123</i>
<i>FIGURE 19 MAJOR GENERICS MARKETS, THROUGH 2016 (\$ BILLIONS)</i>	<i>124</i>
OVERVIEW.....	124
OVERVIEW (CONTINUED)	125
<i>TABLE 18 GLOBAL PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2016 (\$ BILLIONS)</i>	<i>126</i>
<i>TABLE 18 (CONTINUED)</i>	<i>127</i>

RECENT HISTORY OF THE GENERICS SECTOR.....	128
ROCHE-BOLAR	128
GENERICS LOBBY	129
ICH.....	130
THE NEW GENERICS ERA	131
THE PATENT CLIFF	132
<i>TABLE 19 FIRST PATENT EXPIRIES, 2012–2023</i>	<i>133</i>
TYPES OF GENERICS	134
“SIMPLE” GENERICS.....	134
Factors Influencing the Success or Failure of Generics.....	134
Adequate Market Size	134
Patent-Expired Therapies	134
Older Products Still Used.....	135
Long-Term Use.....	135
Straightforward Production Technology.....	136
Drugs Used in Primary Care.....	136
SUPERGENERICS	137
BIOSIMILARS.....	137
Biosimilars (Continued)	138
<i>TABLE 20 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS,</i> <i>2001–2006</i>	<i>139</i>
Special Challenges.....	140
Special Challenges (Continued)	141
The Biosimilar Market	142
Some Biosimilar Developments and Introductions.....	142
EPO	142
G-CSF	143
Interferons.....	143
HGH.....	143
Monoclonal Antibodies.....	144
Monoclonal Antibodies (Continued).....	145
 CHAPTER SIX: VACCINE TECHNOLOGIES AND GLOBAL MARKETS (PHM014D).....	 146
INTRODUCTION	146
STUDY OBJECTIVES	146
REASONS FOR DOING THIS STUDY	146
INTENDED AUDIENCE.....	147
SCOPE OF THE STUDY	147
METHODOLOGY.....	147
INFORMATION SOURCES	147
ABOUT THE AUTHOR	148
RELATED BCC RESEARCH REPORTS.....	148
EXECUTIVE SUMMARY.....	149

<i>TABLE 21 GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, THROUGH 2015 (\$ MILLIONS)</i>	150
<i>FIGURE 20 GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, 2008–2015 (\$ MILLIONS)</i>	151
INDUSTRY STRUCTURE	151
WHO-PREQUALIFIED VACCINE MANUFACTURERS/SUPPLIERS.....	151
<i>TABLE 22 WORLD HEALTH ORGANIZATION (WHO)-PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, 2010</i>	152
MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES.....	153
Attenuated (Live) Vaccines	153
<i>TABLE 23 LEADING MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES</i>	153
<i>TABLE 23 (CONTINUED)</i>	154
Inactivated (Killed) Vaccines	154
<i>TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES</i>	154
<i>TABLE 24 (CONTINUED)</i>	155
CONJUGATE VACCINES.....	155
<i>TABLE 25 LEADING MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES</i>	155
<i>TABLE 25 (CONTINUED)</i>	156
Recombinant/Recombinant DNA (rDNA) Vaccines	156
<i>TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT/ RECOMBINANT DNA (RDNA) VACCINES</i>	156
Subunit Vaccines	157
<i>TABLE 27 LEADING MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES</i>	157
Toxoid Vaccines	157
<i>TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES</i>	157
Combination Vaccines	157
<i>TABLE 29 LEADING MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES</i>	158
MARKET SHARES OF INDUSTRY LEADERS OF HUMAN VACCINES.....	158
Attenuated (Live) Vaccines	159
<i>TABLE 30 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES, 2009 (%)</i>	159
<i>FIGURE 21 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES, 2009 (%)</i>	160
Inactivated (Killed) Vaccines	160

<i>TABLE 31 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES, 2009 (%).....</i>	<i>161</i>
<i>FIGURE 22 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES, 2009 (%).....</i>	<i>161</i>
Conjugate Vaccines.....	162
<i>TABLE 32 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES, 2009 (%).....</i>	<i>162</i>
<i>FIGURE 23 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES, 2009 (%).....</i>	<i>163</i>
Recombinant/Recombinant DNA (rDNA) Vaccines	163
<i>TABLE 33 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%).....</i>	<i>164</i>
<i>FIGURE 24 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%).....</i>	<i>164</i>
Subunit Vaccines	165
<i>TABLE 34 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES, 2009 (%).....</i>	<i>165</i>
<i>FIGURE 25 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF SUBUNIT VACCINES, 2009 (%)</i>	<i>165</i>
Toxoid Vaccines	166
<i>TABLE 35 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES, 2009 (%)</i>	<i>166</i>
<i>FIGURE 26 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF TOXOID VACCINES, 2009 (%).....</i>	<i>166</i>
COMBINATION VACCINES	167
<i>TABLE 36 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES, 2009 (%).....</i>	<i>167</i>
<i>FIGURE 27 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES, 2009 (%).....</i>	<i>167</i>
CHAPTER SEVEN: THE CLINICAL TRIALS BUSINESS (PHM027C)	168
INTRODUCTION	168
STUDY GOALS AND OBJECTIVES	168
REASONS FOR DOING THE STUDY.....	168

INTENDED AUDIENCE.....	169
METHODOLOGY.....	169
ANALYST CREDENTIALS.....	169
SCOPE OF REPORT.....	170
INFORMATION SOURCES.....	170
RELATED BCC REPORTS.....	170
SUMMARY.....	171
<i>TABLE 37 U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, THROUGH 2014.....</i>	<i>172</i>
<i>FIGURE 28 U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, 2009–2014 (\$ BILLIONS).....</i>	<i>173</i>
OVERVIEW.....	173
TYPES OF CLINICAL TRIALS.....	173
CLINICAL TRIAL PHASES.....	174
WHO SPONSORS CLINICAL TRIALS?.....	174
<i>TABLE 38 U.S. FORECAST OF SPONSORED CLINICAL TRIALS, THROUGH 2014.....</i>	<i>174</i>
<i>FIGURE 29 U.S. SPONSORED CLINICAL TRIALS MARKET, 2009– 2014 (\$ BILLIONS).....</i>	<i>175</i>
<i>FIGURE 30 DRUG DEVELOPMENT TIME LINE.....</i>	<i>176</i>
<i>TABLE 39 PHASES OF THE CLINICAL TRIAL.....</i>	<i>176</i>
PHASE I.....	177
PHASE II.....	177
PHASE III.....	178
PHASE IV/POST-MARKETING TRIALS.....	178
FACTORS AFFECTING STUDY SIZE.....	178
PHYSICIAN AND PATIENT RECRUITMENT.....	179
U.S. GOVERNMENT REGULATIONS.....	180
PHARMACEUTICALS AND BIOLOGICS.....	180
<i>TABLE 40 U.S. LAWS AFFECTING DRUG APPROVAL TIMES.....</i>	<i>180</i>
Additional U.S. Laws Affecting Clinical Trials.....	180
Health Insurance Portability and Accountability Act of 1996 (HIPAA).....	180
Best Pharmaceuticals for Children Act (BPCA), 2002.....	181
<i>TABLE 41 TOTAL APPROVED ACTIVE MOIETIES WITH NO MARKETING PROTECTION FOR WHICH FDA HAS ISSUED A WRITTEN REQUEST.....</i>	<i>182</i>
FOOD AND DRUG ADMINISTRATION (FDA).....	182
Background.....	182
Center for Biologics Evaluation and Research (CBER).....	183
CBER and Bioterrorism.....	184
Center for Drug Evaluation and Research (CDER).....	184
CDER and Bioterrorism.....	184

Critical Path Initiative (CPI)	185
MEDICAL DEVICES	185
Center for Devices and Radiologic Health (CDRH)	185
Articles Subject to Medical Device Amendments	185
Classification of Devices (General Section 513)	186
Class I—General Controls	186
Class II—Special Controls	186
Class III	187
Expedited Review	187
<i>FIGURE 31 NEW DRUG DEVELOPMENT</i>	187
<i>TABLE 42 CDER APPROVAL TIMES FOR PRIORITY AND STANDARD</i> <i>NDAS AND BLAS, CALENDAR YEARS, 1993–2008</i>	188
Expedited Development and Review	188
<i>TABLE 43 FIRST CYCLE APPROVAL RATE FOR OVERALL STUDY</i> <i>COHORT BY YEAR, 2002–2007</i>	189
Subpart E	189
Accelerated Approval (Subpart H)	190
Priority Review	190
Fast Track	190
<i>TABLE 44 NUMBER AND TOTAL APPROVAL TIME (IN MONTHS) OF</i> <i>APPROVED NDAS AND BLAS BY FISCAL YEAR OF SUBMISSION</i> <i>AND BY REVIEW PROCEDURE</i>	191
Pediatrics	191
U.S. LITIGATION AND CLINICAL TRIALS	191
<i>TABLE 45 INSURANCE COMPANIES OFFERING CLINICAL TRIAL</i> <i>LIABILITY INSURANCE</i>	192
INVESTIGATIONAL REVIEW BOARD (IRB)	192
INVESTIGATIONAL REVIEW BOARD (CONTINUED)	193